Department of Neurosurgery, University Clinic, Navarra, Spain.
Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
J Neurooncol. 2019 Feb;141(3):487-494. doi: 10.1007/s11060-018-03087-7. Epub 2019 Jan 3.
5-aminolevulinic acid (5-ALA) was approved by the FDA in June 2017 as an intra-operative optical imaging agent for patients with gliomas (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery. 5-ALA fluorescence-guided surgery (FGS) has been in widespread use in Europe and other continents since 2007.
We reviewed the data available and summarize the most important known uses of 5-ALA FGS and its potential future applications.
RESULTS/CONCLUSIONS: The technique has been extensively studied, and more than 300 papers have been published on this topic. Visualization of high-grade glioma tissue is robust and reproducible, and can impact the extent of tumor resection and patient outcomes. 5-ALA FGS for other kind of tumors needs further development.
5-氨基酮戊酸（5-ALA）于 2017 年 6 月获得美国食品药品监督管理局（FDA）批准，作为胶质瘤患者术中的光学成像剂（术前影像学怀疑为世界卫生组织[WHO]分级 III 或 IV 级），用于在手术中观察恶性组织。自 2007 年以来，5-ALA 荧光引导手术（FGS）已在欧洲和其他大洲广泛应用。
我们回顾了现有数据，并总结了 5-ALA FGS 的最重要的已知用途及其潜在的未来应用。
结果/结论：该技术已得到广泛研究，已有 300 多篇关于该主题的论文发表。高级别胶质瘤组织的可视化效果可靠且可重现，可影响肿瘤切除范围和患者预后。5-ALA FGS 用于其他类型肿瘤尚需进一步开发。
